Deborah Palestrant

Deborah Palestrant, Ph.D., M.B.A joined 5AM Ventures in 2018 as Partner and Executive Chair of 4:59 Initiative.
Previously, Dr. Palestrant was Vice President of Corporate Development & Strategy at Relay Therapeutics, where she executed business strategy including alliances, partnerships, and other collaborations and led communications.
She has over 15 years of life sciences industry experience including drug discovery, company creation, operations, business development, and strategy.
Following her postdoctoral fellowship, Dr. Palestrant was a lab head at the Novartis Institutes for Biomedical Research, where she advanced multiple structure-based drug discovery programs.
In 2010, Dr. Palestrant joined Third Rock Ventures as a senior associate and helped to build and launch Blueprint Medicines (NASDAQ: BPMC).
Upon its launch, Dr. Palestrant served an interim role in operations at Blueprint Medicines.
Subsequent to her return to Third Rock Ventures, Dr. Palestrant helped to conceive and launch Editas Medicine (NASDAQ: EDIT), and as part of the original founding team, she led the business development group until joining Relay Therapeutics.
Dr. Palestrant holds a Ph.D.
in biochemistry and molecular biophysics from Columbia University, an M.B.A from Northeastern University, and was Damon Runyon Cancer Research Foundation Postdoctoral Fellow at The Scripps Research Institute.
She is based in the Boston, MA office.